At the 2019 ATS conference in Dallas, TX, USA, Nick Hanania (Baylor College of Medicine, Houston, TX, USA), discusses unmet needs in the management of patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) at risk of exacerbations; the budesonide/formoterol fumarate metered dose inhaler (BFF MDI) and how it differs from other COPD inhaled corticosteroid/bronchodilator combination; and the impact of BFF MDI on patients with COPD assessed in the SOPHOS study.
1. What unmet needs currently exist in the management of patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) at risk of exacerbations? (0:04)
2. Please briefly describe the budesonide/formoterol fumarate metered dose inhaler (BFF MDI) and how it differs from other COPD inhaled corticosteroid/bronchodilator combinations. (0:56)
3. How was the impact of BFF MDI on patients with COPD assessed in the SOPHOS study? (1:52)
4. Briefly outline the main findings of the SOPHOS study. (2:57)
5. What implications do these results have for COPD management? (4:22)
Speaker disclosure: Nick Hanania has nothing to disclose in relation to this video interview.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at ATS 2019, Dallas, TX, USA, May 2019.
Share this Video
Related Videos In COPD
Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial
It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!